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Abstract
Purpose Deciding whether to re-operate patients with intracranial tumor recurrence or remnant is challenging, as the data on 
safety of repeated procedures is limited. This study set out to evaluate the risks for morbidity, mortality, and complications 
after repeated operations, and to compare those to primary operations.
Methods Retrospective observational two-center study on consecutive patients undergoing microsurgical tumor resection. 
The data derived from independent, prospective institutional registries. The primary endpoint was morbidity at 3 months 
(M3), defined as significant decrease on the Karnofsky Performance Scale (KPS). Secondary endpoints were mortality, rate 
and severity of complications according to the Clavien–Dindo Grade (CDG).
Results 463/2403 (19.3%) were repeated procedures. Morbidity at M3 occurred in n = 290 patients (12.1%). In univariable 
analysis, patients undergoing repeated surgery were 98% as likely as patients undergoing primary surgery to experience 
morbidity (OR 0.98, 95% CI 0.72–1.34, p = 0.889). In multivariable analysis adjusted for age, sex, tumor size, histology and 
posterior fossa location, the relationship remained stable (aOR 1.25, 95% CI 0.90–1.73, p = 0.186). Mortality was n = 10 
(0.4%) at discharge and n = 95 (4.0%) at M3, without group differences. At least one complication occurred in n = 855, and 
the rate (35.5% vs. 35.9%, p = 0.892) and severity (CDG; p = 0.520) was similar after primary and repeated procedures. 
Results were reproduced in subgroup analyses for meningiomas, gliomas and cerebral metastases.
Conclusions Repeated surgery for intracranial tumors does not increase the risk of morbidity. Mortality, and both the rate 
and severity of complications are comparable to primary operations. This information is of value for patient counseling and 
the informed consent process.
Keywords Brain tumor · Craniotomy · Complications · Mortality · Morbidity · Reoperation
Introduction
Neurosurgeons strive to cure patients from intracranial 
tumors with a single operation, thus obviating the need for 
further interventions. Unfortunately, additional procedures 
are often necessary, mostly because of incomplete resec-
tion during the primary surgery, as well as recurrence. The 
question of whether to re-operate can be challenging, and 
many factors, including a patient’s clinical presentation 
and cancer prognosis, must be taken into consideration. In 
general, it is essential for therapeutic decision-making and 
informed consent to have robust estimates of both the ben-
efits and the risks of a given treatment. This is particularly 
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true in situations where therapeutic alternatives to surgery 
can be offered, such as radiotherapy and/or chemotherapy.
In daily clinical patient care, we experience both favora-
ble and unfavorable effects of repeated surgeries for intrac-
ranial tumors. Intervening repeatedly is sometimes consid-
ered more difficult, as delicate anatomical structures have 
already been manipulated and both scarring and adhesions 
may interfere with the dissection [1]. Moreover, dural clo-
sure and wound healing may be more difficult, and infection 
rates higher. For these reasons, previous reports had pointed 
out higher morbidity and complication rates for repeated 
surgery [2–4]. On the other hand, the previously established 
surgical access may facilitate certain procedures, and thus 
support re-operation.
Given the scarcity of literature on this topic, we set out 
to investigate whether the risk profile of a repeated tumor 
resection is comparable to that of the initial procedure.
Methods
Study type and inclusion criteria
We performed a retrospective observational two-centre 
study, involving consecutive patients undergoing microsur-
gical resection of intracranial tumors via open craniotomy.
For this, we pooled institutional data from patients treated 
between 01/2013 and 12/2017 at the Department of Neuro-
surgery, University Hospital Zurich, Switzerland (USZ), and 
between 01/2014 and 12/2017 at the Department of Neu-
rosurgery, Fondazione IRCCS Istituto Neurologico Carlo 
Besta Milan, Italy (IRCCS). Methodological details of the 
patient registries at USZ and IRCCS were described previ-
ously [5–7].
The sample was dichotomized into “repeated surgeries” 
(= study group; patients having undergone microsurgical 
resection of an intracranial tumor before) versus “primary 
surgeries” (control group; patients not having undergone 
microsurgical resection of an intracranial tumor before). 
Diagnostic biopsies were not considered as “surgery” in this 
context. Few patients of both groups might have undergone 
diagnostic sampling prior to surgery, to rule out lymphoma 
or non-neoplastic lesion (data not available). Also, patients 
operated via trans-sphenoidal access (TSS) were omitted 
from analysis, considering their distinct complication and 
outcome profile.
Endpoints and recorded variables
The primary endpoint was postoperative morbidity, defined 
as a significant change on the Karnofsky Performance Scale 
(KPS) at 3-months follow-up (M3), compared to the preop-
erative status. As there is no established “minimum clinically 
important difference” of the KPS after neuro-oncological 
surgery and a 10-point change on the upper KPS is not as 
meaningful to a patient as a 10-point change on the lower 
KPS, we adapted the previous definition for “significant 
change” as a decrease of ≥ 20 points if baseline KPS ≥ 80, 
or a decrease of ≥ 10 points if baseline KPS < 80 [8]. The 
KPS scale was chosen for its close correlation to surgery-
related outcomes and its predictive capacity for morbidity 
in intracranial tumor patients [6, 9].
Secondary endpoints were morbidity at discharge, mor-
tality, length of hospitalization (LOH), as well as rate, type 
and severity of complications. Any deviation from the nor-
mal postoperative course was considered a complication, 
including adverse events that are sometimes expected (e.g. 
visual field deficit after resection of a glioma in the visual 
cortex), even when considered as acceptable or unavoidable 
in a clinical setting. Complications were classified according 
to two different systems: the Clavien–Dindo Grade [CDG; 
ranging from I (no intervention needed) to V (complica-
tion resulting in death; see Online Resource 1)] [10], and 
an etiological classification proposed by Ferroli et al. [7]: 
traumatic (i.e. directly related to the surgical manipulation), 
cerebrospinal fluid (CSF)-related (i.e. leaks, hydrocephalus), 
septic, hemorrhagic, ischemic, epileptic, general [non-cen-
tral nervous system (CNS)] and other. In cases with multiple 
documented complications, the most severe one was chosen 
for statistical analysis.
Other variables recorded were: general patients’ demo-
graphics (age, sex), tumor type and size, eloquent and poste-
rior fossa location. Eloquent areas were considered as motor, 
sensory, language or visual areas, hypothalamus, thalamus, 
internal capsule, brainstem, and pineal region [7]. Difficulty 
of tumor dissection was estimated by the need to manipulate 
major blood vessels and/or cranial nerves [7].
Statistical analysis
Both demographic and disease-specific baseline informa-
tion were described using frequencies and percentages for 
categorical variables. Ordinal variables were described as 
medians and interquartile range (IQR). Interval variables 
were described as group means and standard deviations 
(SD). Imbalances were tested using Pearson χ2 tests, Wil-
coxon rank sum tests or student’s t tests, as appropriate.
Logistic regression analysis was performed to estimate 
the effect size of the relationship between the variable of 
interest “repeated surgery” and an endpoint. First, a uni-
variable model was built to analyze the direct relationship. 
Then, a multivariable model was created to adjust for base-
line group differences. Results were expressed as (adjusted) 
odds ratios ((a)OR) with 95% confidence intervals (CI), 
analyzed for changes after adjustment. Sensitivity analyses 
were performed. Since the question of safety of repeated 
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operations is important to all tumor types, we combined 
data of patients suffering from a wide range of benign and 
malignant intracranial tumors for our main statistical model. 
We performed subgroup analyses, however, to explore the 
relationship between “repeated procedure” and morbidity 
separately for the three main histopathological tumor types. 
We decided against propensity score matching, as logistic 
regression was found to be superior for analyses with high 
numbers of events per confounder, such as ours [11].
In order to detect a statistically significant difference of 
5% in the primary endpoint (M3 morbidity) with a power of 
0.8 and alpha set at 0.05, a total of at least n = 1856 patients 
would be required with n = 429 in the study and n = 1427 
in the control group. Statistical analyses were performed 
with Stata version 14.2 for Mac (College Station, TX: Stata-
Corp LP). P-values < 0.05 were regarded as statistically 
significant.
Ethical considerations
The scientific workup of registry data was approved by 
the institutional review boards of both institutions and the 
patient’s informed consent was waived. The authors report 
no relevant conflicts of interest.
Results
A total of 2718 patients were identified, of which n = 315 
patients undergoing TSS were omitted. Patient- and dis-
ease-specific information of the remaining 2403 patients 
[mean age 52.7 ± 17.7 years (SD); n = 1229 female (51.1%); 
463 undergoing repeated surgery (19.3%)] is presented in 
Table 1. Patients undergoing repeated surgery were about 
5 years younger, more often male and had slightly smaller 
tumors that were less often located in the posterior fossa. 
Repeated surgeries were most frequently performed for 
glioblastoma (26.2%), followed by meningioma (18.4%) 
and other histological subtypes (12.6%). Otherwise, study 
groups were balanced for baseline functional status and elo-
quent location, besides other surgical features (all p > 0.05; 
Table 1).
Analysis of the primary endpoint
Morbidity at M3 was registered in n = 290 patients 
(12.1%). In univariable analysis, patients undergoing 
repeated surgery were 98% as likely as patients undergo-
ing primary surgery to experience morbidity. We are 95% 
confident that the likelihood ranges between 72 and 134% 
(OR 0.98, 95% CI 0.72–1.34, p = 0.889). In multivariable 
analysis, the adjusted relationship remained insignificant 
and with a small effect size (aOR 1.25, 95% CI 0.90–1.73, 
p = 0.186; Table 2). Sensitivity analyses indicated robust-
ness of the model.
Given the differences in the functional status of included 
patients with different histopathological tumor subtypes, 
subgroup analyses were made for those diagnosed with 
meningioma (n = 664, of which n = 85 repeated; Online 
Resource 2; aOR 0.70, 95% CI 0.20–2.41, p = 0.574), high- 
or low-grade glioma (n = 849, of which n = 220 repeated; 
Online Resource 3; aOR 1.42, 95% CI 0.91–2.23, p = 0.125) 
or cerebral metastasis (n = 357, of which n = 47 repeated; 
Online Resource 4; aOR 1.60, 95% CI 0.77–3.34, p = 0.207), 
respectively, with no significant difference in the morbidity 
risk observed.
Analysis of the secondary endpoints
Morbidity at discharge was registered in n = 294 patients 
(12.2%). In both uni- (OR 0.94, 95% CI 0.68–1.28, 
p = 0.676) and multivariable analyses (aOR 1.06, 95% CI 
0.77–1.47, p = 0.692; Table 3) the odds for morbidity at dis-
charge were not increased in patients undergoing repeated 
surgery. The results were similar for the three histopatho-
logical tumor subtypes (see Online Resources 2–4).
Mortality was n = 10 (0.4%) at discharge, of which no 
death occurred after a repeated procedure (p = 0.122). Mor-
tality was n = 95 (4.0%) at M3, of which 18 deaths occurred 
after a repeated procedure (p = 0.936). The odds for dying 
until 3 months were not increased in patients undergoing 
repeated surgery in both uni- (OR 0.98, 95% CI 0.58–1.65, 
p = 0.936) and multivariable analysis (aOR 1.33, 95% CI 
0.77–2.29, p = 0.307; see Online Resource 5). In patients 
with intracranial meningiomas and cerebral metastases, 
those results could be reproduced (see Online Resources 2 
and 4). M3 mortality was higher in patients with repeated 
glioma surgery, however (aOR 2.95, 95% CI 1.35–6.45, 
p = 0.007; see Online Resource 3).
In-hospital complications occurred in 855 (35.6%) 
patients, and both the rates (35.5% vs. 35.9%, p = 0.892) 
and severity according to the CDG were similar after pri-
mary and repeated procedures (p = 0.520; Table 4). The 
majority of complications in primary vs. repeated surgeries 
were CDG grade I (18.4% vs. 19.2%) and II (8.8% vs. 9.7%), 
therefore not requiring invasive treatment.
The etiology of complications differed significantly 
between the two groups (Table 5; p = 0.005). In both groups, 
traumatic (15.7% vs. 14.0%), general medicine (6.2% vs. 
4.5%) and CSF-related (2.8% vs. 4.3%) causes occurred 
most frequently. The relative frequency of CSF-related, 
ischemic, hemorrhagic complications, but especially epilep-
tic complications (4.1% vs. 1.9%), was higher after repeated 
surgery (Table 5).
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Table 1  Baseline table with 
patient demographics
Data is presented in mean [standard deviation (SD)], median [interquartile range (IQR)] or count (percent)
*Two-sample Wilcoxon rank-sum (Mann–Whitney) test used
+ Two-sample t test used
Primary surgery Repeated surgery p-value
Age in years; mean (SD) 53.8 (17.5) 48.4 (18.2) < 0.001
Sex 0.004
 Male 920 (47.4%) 254 (54.9%)
 Female 1020 (52.6%) 209 (45.1%)
Histopathology < 0.001
 Meningioma 597 (29.9%) 85 (18.4%)
 Glioblastoma 423 (21.8%) 121 (26.2%)
 Adenoma 12 (0.6%) 8 (1.7%)
 Anapl. Astrocytoma 89 (4.6%) 48 (10.4%)
 Low grade glioma 117 (6.0%) 51 (11.0%)
 Metastasis 310 (16.0%) 47 (10.2%)
 Schwannoma 109 (5.6%) 15 (3.3%)
 (Epi-)dermoid 26 (1.3%) 7 (1.5%)
 Chordoma 8 (0.4%) 8 (1.7%)
 Craniopharyngioma 22 (1.1%) 14 (3.0%)
 Other 245 (12.6%) 58 (12.5%)
Admission KPS; median (IQR) 90 (10) 90 (10) 0.756*
Tumor size in cm; mean (SD) 3.75 (1.8) 3.33 (1.6) < 0.001+
Eloquent location 0.488
 Yes 975 (50.3%) 241 (52.0%)
 No 965 (49.7%) 222 (48.0%)
Posterior fossa location 0.009
 Yes 415 (21.4%) 74 (16.0%)
 No 1525 (78.6%) 389 (84.0%)
Major brain vessels manipulation 0.790
 Yes 712 (36.7%) 173 (37.4%)
 No 1228 (63.3%) 290 (62.6%)
Cranial nerve manipulation 0.931
 Yes 499 (25.7%) 120 (25.9%)
 No 1441 (74.3%) 343 (74.1%)
n = 1940 (100%) n = 463 (100%)
Table 2  Uni- and multivariate 
logistic regression analysis 
estimating the relationship 
between repeated microsurgical 
resection of an intracranial 
tumor and morbidity at M3
The multivariable analysis is adjusted for baseline differences in age, sex, histological diagnosis, size and 
posterior fossa location of the tumor
Univariable analysis Multivariable analysis
OR 95% CI p-value aOR 95% CI p-value
Repeated surgery 0.98 0.72–1.34 0.889 1.25 0.90–1.73 0.186
Age (per year) 1.03 1.02–1.04 < 0.001 1.03 1.02–1.04 < 0.001
Male sex 1.54 1.20–1.97 0.001 1.47 1.13–1.90 0.004
Tumor size (per increase in 
category)
1.83 1.46–2.28 < 0.001 1.78 1.41–2.25 < 0.001
Histology 0.98 0.95–1.02 0.349 1.01 0.97–1.06 0.492
Posterior fossa location 1.05 0.78–1.42 0.757 1.39 1.00–2.25 0.047
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LOH was similar between patients undergoing primary 
(8.3 ± 7.7 days (SD)) and repeated surgery (7.9 ± 6.2 days 
(SD); p = 0.340).
Discussion
Ongoing debates in neurosurgery focus on whether repeated 
procedures for the resection of intracranial tumors increase 
the risks for morbidity, mortality and postoperative com-
plications. By analyzing a set of prospectively collected 
data from two independent neurosurgical departments with 
respect to this research question, we demonstrated that the 
risk for morbidity is not increased after repeated, as com-
pared to primary microsurgical tumor resection (aOR 1.25, 
95% CI 0.90–1.73, p = 0.186). We also found a low mortality 
rate in both groups, and similar rates and severity of post-
operative complications. Those findings made in a large, 
heterogeneous cohort (n = 2403) could be reproduced in 
disease-specific subgroup analyses of patients with intrac-
ranial meningiomas (n = 664), high- or low-grade gliomas 
(n = 849) and cerebral metastases (n = 357).
Study groups were defined by dichotomizing the patient 
cohort into first-ever versus repeated tumor resection. Given 
the typical patient distribution of tertiary neuro-oncological 
referral centers, about one in five patients was operated for a 
second (or third) time. Since data of n = 2403 patients from 
two hospitals was pooled, a reasonably sized study group 
(n = 463; 19.3%) could be compared to n = 1940 controls. 
The found relationships are credible, owing to the typical 
characteristics of the study group (Table 1), internal consist-
ency within the two independent datasets, and the results 
matching our personal clinical observations. The repeat-
surgery sample consisted of the typical patient cohort that 
is prone to re-operations: younger patients with high-grade 
gliomas (HGG) or meningiomas of medium size that have 
kept a reasonably good functional status. Here again, the 
observed patient characteristics compare well with the 
expected ones, indicating validity of the analyzed data. The 
study and control groups were balanced for many baseline 
characteristics. Importantly, the admission KPS—a factor 
recently shown to influence postoperative mortality, morbid-
ity and complications—was similar between the two groups 
[6]. The main statistical model was otherwise adjusted for 
Table 3  Logistic regression 
analysis estimating the 
relationship between repeated 
microsurgical resection of 
an intracranial tumor and 
morbidity at discharge
The multivariable analysis is adjusted for baseline differences in age, sex, histological diagnosis, size and 
posterior fossa location of the tumor
Univariable analysis Multivariable analysis
OR 95% CI p-value aOR 95% CI p-value
Repeated surgery 0.94 0.68–1.28 0.676 1.07 0.77–1.47 0.692
Age (per year) 1.01 1.00–1.02 0.029 1.01 1.00–1.02 0.006
Male sex 1.21 0.95–1.55 0.124 1.19 0.93–1.53 0.171
Tumor size (per increase in 
category)
1.38 1.11–1.71 0.004 1.43 1.14–1.79 0.002
Histology 1.02 0.98–1.05 0.360 1.02 0.98–1.06 0.305
Posterior fossa location 1.58 1.20–2.09 0.001 1.76 1.31–2.35 < 0.001
Table 4  Rate and severity of worst postoperative complication until 
discharge, according to the Clavien Dindo Grade (CDG).[10]
CDG Primary surgery Repeated surgery p-value
None 1251 (64.5%) 297 (64.2%) 0.892
I 357 (18.4%) 89 (19.2%) 0.520
II 171 (8.8%) 45 (9.7%)
III a 40 (2.1%) 11 (2.4%)
III b 79 (4.1%) 18 (3.9%)
IV a 27 (1.4%) 3 (0.6%)
IV b 6 (0.3%) − (0%)
V 9 (0.4%) − (0%)
n = 1940 (100%) n = 463 (100%)
Table 5  Etiology of postoperative complication until discharge, 
according to the classification by Ferroli et al. [7]
Etiological category Primary surgery Repeated surgery p-value
None 1251 (64.5%) 297 (64.2%) 0.892
Traumatic 304 (15.7%) 65 (14.0%) 0.005
CSF-related 55 (2.8%) 20 (4.3%)
Septic 41 (2.1%) 2 (0.4%)
Ischemic 55 (2.8%) 18 (3.9%)
Hemorrhagic 53 (2.7%) 15 (3.2%)
General medicine 120 (6.2%) 21 (4.5%)
Epileptic 37 (1.9%) 19 (4.1%)
Other 24 (1.2%) 6 (1.3%)
n = 1940 (100%) n = 463 (100%)
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variables that differed between the groups. Owing to the 
large sample size and robust endpoint, we can provide accu-
rate estimates for the effect size of the relationship between 
“repeated surgery” and morbidity with tight confidence 
intervals for the main statistical model. The results were 
consistent in subgroup analyses for the most prevalent tumor 
subtypes and additional sensitivity analyses. Internal con-
sistency is furthermore evident by similarity in the result of 
each of the analyzed outcome measures (morbidity, mortal-
ity, complication rate and severity, LOH).
When a surgeon has to choose whether or not to operate 
on a patient, he/she will balance the possible advantages 
with disadvantages in order to estimate the risks and benefits 
of the operation itself. This evaluation becomes more chal-
lenging in case of repeated surgical interventions, as their 
risks can be estimated less well.
In general surgery, there are advocates of an increased 
risk of repeated surgeries [12, 13], while others present 
more optimistic results [14, 15]. In neurosurgery, repeated 
procedures are most frequently performed for recurrence 
of intracranial tumors with a high tendency for re-growth 
despite macroscopically complete resection and/or adjuvant 
treatment. For HGG, atypical meningiomas or chordomas, 
for example, re-operation rates between 8–45% have been 
described [16–18]. Thus, besides reflecting upon the onco-
logical benefit [17, 19–25], the surgeon must decide whether 
or not the safety of repeated procedures is given.
In theory, several aspects such as e.g. scarring of critical 
structures or prior dural opening can increase the difficulty 
of microsurgical tumor dissection or complicate dural clo-
sure. Moreover, wound closure defects/delay secondary to 
the use of adjuvant chemotherapy and/or radiotherapy [26, 
27] and an increased rate of postoperative infections [3, 4] 
have been associated with repeated surgery. On the other 
hand, a previously established surgical corridor may also 
facilitate the access to the lesion. According to our own sur-
gical experience, repeated operations are technically more 
difficult, but the present data indicate that careful patient 
care does not necessarily translate into worse outcomes, as 
discussed below.
In the literature, not much is present on the topic, with 
the majority of the articles focusing on HGGs owing to their 
high recurrence rates [22, 28].
Concerning the oncological benefit, the current litera-
ture indicates improved survival time in carefully selected 
patients undergoing repeated surgery [22, 23, 28–30]. Con-
cerning the risks, Chang et al. found that there was a modest 
trend toward increased perioperative complications among 
patients undergoing repeated craniotomy, despite similar 
length of surgery [4]. In their cohort, there was also an 
increased risk for systemic infections and depression, while 
the rates of wound infections, seizures, thromboembolic or 
hemorrhagic complications were similar to those of patients 
undergoing primary surgeries. Since most patients remained 
in a neurologically stable or improved condition, the authors 
considered the safety of repeated surgeries acceptable [4]. 
Besides, the authors found preoperative KPS score and 
tumor size as predictive of outcome, which compares well 
to our previous and present results [6].
The evaluation of repeated surgery for other tumor types 
[e.g., low-grade gliomas (LGG), adenomas, metastases, 
meningiomas] is much less accounted for. However, an 
increase in overall survival and a moderate increase in risk 
emerge from the literature for recurrent adult [31–37] and 
pediatric brain tumors [26].
Morbidity and mortality
Our present article adds important, prospectively collected 
data on complications and outcomes to the existing body of 
literature. Our rates of in-hospital mortality (0.0%; 0/463 
procedures) and morbidity at discharge (11.7%; 54/463 pro-
cedures) were equally low after repeated as compared to 
primary surgery. Also after adjustment for baseline group 
differences, patients undergoing repeated surgery were as 
likely as patients undergoing primary surgery to experi-
ence discharge morbidity, showing no adverse effect of re-
operations on the functional outcome immediately after the 
intervention. Independent factors that were found predictive 
of morbidity at discharge were posterior fossa location of 
the tumor (aOR 1.76, 95% CI 1.31–2.35), increase in tumor 
size category (aOR 1.43, 95% CI 1.14–1.79) and higher age 
(aOR 1.01, 95% CI 1.00–1.02; Table 3). Those findings are 
not surprising, as the posterior fossa contains vital struc-
tures such as the brainstem, but also dissecting tumors in the 
vicinity of cranial nerves is more likely to result in morbid-
ity. Posterior fossa surgery is known to have an increased 
rate of complications compared to supra-tentorial surgery, in 
particular CSF-leakage [38]. Moreover, the removal of larger 
tumors usually results in more affection of the surround-
ing vital brain tissue and those challenging procedures are 
known to have more impact on elder patients [39]. The fact 
that those well-known observations can be detected in our 
analysis, however, lends credibility to the underlying data-
set. Disease-specific subgroup analyses confirmed the results 
(see Online Resources 2–4), with stable effect sizes indicat-
ing a similar risk of first-ever or repeated craniotomies for 
intracranial meningiomas, high- and low-grade gliomas and 
cerebral metastases at time of discharge.
The results at discharge are particularly interesting in this 
regard, as they relate more directly to the surgical procedure, 
whereas the M3 follow-up results may already be influenced 
by the natural disease course. Accordingly, despite a similar 
likelihood for morbidity and mortality after repeated pro-
cedures for the complete cohort (see Table 2 and Online 
Resource 5), we noticed higher odds for M3 mortality in 
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glioma patients who underwent repeated surgery. Since there 
was no discharge mortality in patients undergoing repeated 
surgery and discharge morbidity was similar in glioma 
patients (see Online Resource 3), the higher M3 mortality in 
this patient cohort is likely more related to disease progres-
sion than to the surgery itself. Repeated surgical procedures 
in patients with high-grade gliomas sometimes represent 
“salvage procedures”, when options with radiation therapy 
and chemotherapy have been exhausted. The effect of this 
group with particularly dismal prognosis can be appreciated 
in our dataset.
Complications and LOH
Previous studies have demonstrated an increased risk for 
perioperative complications after repeated neurosurgery 
[4, 26, 40]. However, these works included smaller patient 
cohorts, and none used validated grading systems for com-
plications. In our series, both the overall rate of complica-
tions, as well as their severity according to the CDG was 
comparable. The majority of the complications both in the 
primary and in the repeated surgery groups were minor 
(grade I or II). Besides the methodological differences of 
our study compared to the previous ones [4, 26, 40], our 
more favorable results in repeated procedures could be due 
to increased awareness for the challenges of repeated sur-
gery, as well as recent advances in neurosurgical techniques, 
neuro-anesthesia and neuro-critical care [4, 41].
Our analysis showed some differences in the etiology of 
complications between the study groups, with CSF-related, 
ischemic/hemorrhagic and epileptic complications being 
increased in the repeated surgery group. In particular the 
relative frequency of seizures after repeated operations was 
twice as high as the one following primary surgery (4.1% 
vs. 1.9%). This finding could be indicative of more irritable 
or vulnerable brain parenchyma after repeated surgery. The 
marginally higher rate of CSF-related complications could 
have a number of explanations, including previous opening 
and re-adaptation of the dura and the need for autologous 
or allogeneic dural substitute for closure. More research is 
needed, however, to confirm these observations. As only the 
complication with highest CDG was recorded, the present 
data do not allow for the calculation of complication-specific 
incidence rates.
Strengths and limitations
Strengths include the prospective collection of large and 
independent datasets from two hospitals in different coun-
tries, which reduces bias, as management strategies varied, 
and allows for generalization to other centers. Variable defi-
nitions and the design of both patient registries were unified. 
We chose defined outcomes and endpoints, and intentionally 
applied simple but adequate statistical approaches to address 
a pre-specified hypothesis with the least amount of statisti-
cal tests in order to avoid type-I errors. Given the relatively 
large sample size, the study had enough power to exclude 
a between-group difference of 5% in the primary endpoint.
Limitations include cohort heterogeneity, especially 
concerning the histopathological diagnosis, which is why 
disease-specific subgroup analyses are provided. Also, selec-
tion bias may apply and the results should not be generalized 
to the whole populations of patients presenting with recur-
rent tumors. Once a patient presents with tumor recurrence, 
surgeons tend to propose surgery as primary treatment to 
patients that have a reasonable chance to obtain a favorable 
outcome (higher KPS, younger age, etc.). On the contrary, 
for those patients deemed unsuitable for surgery alternative 
treatment (radiosurgery, radiotherapy, chemotherapy) is 
more frequently considered. Patients undergoing repeated 
surgery might therefore be subject to a survival bias. As for 
answering this particular research question a randomized 
controlled trial is not possible, best evidence will need to 
derive from retrospective analysis of prospective, high-
quality databases. Results must be interpreted within the 
limitations of its design. Moreover, as we did not analyze 
long-term survival, we could not estimate the oncological 
benefit of repeated operations. Additional analyses of the 
impact of adjuvant radio- and chemotherapy on the risk for 
postoperative complications would have been interesting; 
future studies should explore these issues.
Conclusions
Repeated surgical procedures for intracranial tumors in 
general do not increase the risk of morbidity in carefully 
selected candidates, compared to primary surgeries. The rate 
and severity of complications is comparable, and mortality 
is equally low. Those findings made in a large, heterogene-
ous cohort could be reproduced in disease-specific subgroup 
analyses of patients with intracranial meningiomas, gliomas 
and cerebral metastases. When considering repeated surgery, 
this information will be of value for patient counseling and 
the informed consent process.
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